-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Since the beginning of this year, with the accelerated changes in the pharmaceutical market environment, many pharmaceutical companies have chosen to "run awa.
The reasons for these executives' resignation include work reasons, personal reasons, job adjustment, retirement, e.
Mainly for personal reaso.
In the second half of the year, from the current point of view, the resignation wave of pharmaceutical industry companies is still continui.
Since July, there have been a large number of companies, and executives such as general managers and deputy general managers have le.
For example, on July 27, Sino Biopharmaceutical announced that Li Yi had resigned as the company's executive director and chief executive because of his intention to focus on other business development, effective July 28, 202On the same day, Li Yi was hired as a senior consultant of the compa.
In addition, Xie Chengrun was appointed as the company's chief executive officer, effective July 28, 202According to public information, Li Yi worked for JPMorgan Chase for 5 years before taking up his post in China Biopharmaceuticals, and was appointed as the first newly established foreign-controlled joint venture securities company JPMorgan Chase Securities (China) .
, L.
in September 201 Chairman of the compa.
Two years ago, Li Yi succeeded Xie Bing as chief executive of Sino Biopharmaceutica.
On July 22, Huaren Pharmaceutical's board of directors received the resignation report of the company's executive president, Bu Guox.
Bu Guoxiu applied for his resignation as CEO due to personal reasons, and will no longer hold other positions in the company and its subsidiaries after his resignati.
According to the company's annual report disclosed in 2021, the total pre-tax remuneration received by Bu Guoxiu from the company was 3333 million yu.
On July 15, Puluo Pharmaceutical announced that the company's board of directors received a written resignation report submitted by the company's deputy general manager Tang Erqi.
Tang Erqing applied to resign from the position of deputy general manager of the company due to personal reasons, and will no longer hold any position in the company after his resignati.
The company's annual report disclosed in 2021 shows that Tang Erqing's total pre-tax remuneration from the company is 810,000 yu.
.
According to incomplete statistics, in the first half of this year, a total of 150 senior executives in the pharmaceutical industry have left, involving multinational pharmaceutical companies, local Biotech, traditional pharmaceutical companies, Internet medical companies, e.
There were also 213 personnel appointments in the first half of the ye.
On the whole, the departure of pharmaceutical company executives has already become the norm in the context of medical reform, but it is worth noting that the current pharmaceutical company executives "group resignation" is becoming more and more freque.
For example, BeiGene has resigned many senior executives this year: in February, Ben Yong resigned as chief medical officer of immuno-oncology; in March, Huang Weijuan resigned as chief medical officer of hematology; in June, Liu Yan resign.
Heavy Pharmaceutical Holdings has also had a number of executive changes this ye.
On May 9, Ding Changtian applied for his resignation as a director of the company, a member of the Strategic Development and Investment Committee of the Board of Directors, and a member of the Remuneration and Assessment Committee of the Board of Directors for personal reasons; on March 11, Heavy Pharmaceutical Holdings received the resignation report of Chairman Liu Shaoyun; also in March, the company announced the resignation of Deputy General Manager and Chief Financial Officer Zhang Ho.
On June 8, Pien Tze Huang released 4 executive change announcements in a r.
A total of 5 executives resigned, and the reasons for their resignation were all work adjustmen.
The announcement shows that the senior executives who have left this time include: director, board secretary, deputy general manager Chen Jipeng, director Lin Liuqiang, supervisor (chairman of the board of supervisors) Hong Dongming, supervisor He Jianguo and supervisor Wu Xiaoh.
Guangyuyuan also resigned three vice presidents within a month: On June 21, Guangyuyuan announced the resignation of vice presidents Zhang Yi and Liang Pe.
Both Zhang Yi and Liang Peng resigned as vice presidents for personal reaso.
no longer hold any positio.
On May 19, Vice President Fu Shuhong resigned, just over a month after Zhang Yi and Liang Peng applied for their resignati.
Analysts believe that under the background of industry changes and intensified competition, the adjustment of the pharmaceutical industry will continue to accelerate in 2022, and in order to cope with the market environment, the changes of executives of pharmaceutical companies will become more freque.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
The reasons for these executives' resignation include work reasons, personal reasons, job adjustment, retirement, e.
Mainly for personal reaso.
In the second half of the year, from the current point of view, the resignation wave of pharmaceutical industry companies is still continui.
Since July, there have been a large number of companies, and executives such as general managers and deputy general managers have le.
For example, on July 27, Sino Biopharmaceutical announced that Li Yi had resigned as the company's executive director and chief executive because of his intention to focus on other business development, effective July 28, 202On the same day, Li Yi was hired as a senior consultant of the compa.
In addition, Xie Chengrun was appointed as the company's chief executive officer, effective July 28, 202According to public information, Li Yi worked for JPMorgan Chase for 5 years before taking up his post in China Biopharmaceuticals, and was appointed as the first newly established foreign-controlled joint venture securities company JPMorgan Chase Securities (China) .
, L.
in September 201 Chairman of the compa.
Two years ago, Li Yi succeeded Xie Bing as chief executive of Sino Biopharmaceutica.
On July 22, Huaren Pharmaceutical's board of directors received the resignation report of the company's executive president, Bu Guox.
Bu Guoxiu applied for his resignation as CEO due to personal reasons, and will no longer hold other positions in the company and its subsidiaries after his resignati.
According to the company's annual report disclosed in 2021, the total pre-tax remuneration received by Bu Guoxiu from the company was 3333 million yu.
On July 15, Puluo Pharmaceutical announced that the company's board of directors received a written resignation report submitted by the company's deputy general manager Tang Erqi.
Tang Erqing applied to resign from the position of deputy general manager of the company due to personal reasons, and will no longer hold any position in the company after his resignati.
The company's annual report disclosed in 2021 shows that Tang Erqing's total pre-tax remuneration from the company is 810,000 yu.
.
According to incomplete statistics, in the first half of this year, a total of 150 senior executives in the pharmaceutical industry have left, involving multinational pharmaceutical companies, local Biotech, traditional pharmaceutical companies, Internet medical companies, e.
There were also 213 personnel appointments in the first half of the ye.
On the whole, the departure of pharmaceutical company executives has already become the norm in the context of medical reform, but it is worth noting that the current pharmaceutical company executives "group resignation" is becoming more and more freque.
For example, BeiGene has resigned many senior executives this year: in February, Ben Yong resigned as chief medical officer of immuno-oncology; in March, Huang Weijuan resigned as chief medical officer of hematology; in June, Liu Yan resign.
Heavy Pharmaceutical Holdings has also had a number of executive changes this ye.
On May 9, Ding Changtian applied for his resignation as a director of the company, a member of the Strategic Development and Investment Committee of the Board of Directors, and a member of the Remuneration and Assessment Committee of the Board of Directors for personal reasons; on March 11, Heavy Pharmaceutical Holdings received the resignation report of Chairman Liu Shaoyun; also in March, the company announced the resignation of Deputy General Manager and Chief Financial Officer Zhang Ho.
On June 8, Pien Tze Huang released 4 executive change announcements in a r.
A total of 5 executives resigned, and the reasons for their resignation were all work adjustmen.
The announcement shows that the senior executives who have left this time include: director, board secretary, deputy general manager Chen Jipeng, director Lin Liuqiang, supervisor (chairman of the board of supervisors) Hong Dongming, supervisor He Jianguo and supervisor Wu Xiaoh.
Guangyuyuan also resigned three vice presidents within a month: On June 21, Guangyuyuan announced the resignation of vice presidents Zhang Yi and Liang Pe.
Both Zhang Yi and Liang Peng resigned as vice presidents for personal reaso.
no longer hold any positio.
On May 19, Vice President Fu Shuhong resigned, just over a month after Zhang Yi and Liang Peng applied for their resignati.
Analysts believe that under the background of industry changes and intensified competition, the adjustment of the pharmaceutical industry will continue to accelerate in 2022, and in order to cope with the market environment, the changes of executives of pharmaceutical companies will become more freque.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
